Revital Mandil–Levin
Director/Board Member at NEUROSENSE THERAPEUTICS LTD.
Net worth: 30 808 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alon Ben-Noon | M | 45 | 7 years | |
| Christine Pellizzari | F | 56 | 3 years | |
| Rachela Popovtzer | F | - |
Nanocarry Therapeutics Ltd.
 Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | - |
| Cary Claiborne | M | 64 | 3 years | |
| Caren Deardorf | F | 59 | 3 years | |
| Oron Yacoby-Zeevi | M | 63 | 11 years | |
| Mark Leuchtenberger | M | 67 | 3 years | |
| Oshra Betzer | M | - |
Nanocarry Therapeutics Ltd.
Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | - |
| Shiran Zimri | M | - | 4 years | |
| Anat Nahmany | F | - | 8 years | |
| Irit Shefer | F | - | 2 years | |
| Diana Shtossel | F | - | 2 years | |
| Nedira Salzman-Frenkel. | F | - | 2 years | |
| Ferenc Tracik | M | 60 | 3 years | |
| Mikio Himizu | M | - | 7 years | |
| Ziva Mesika | F | 60 | 8 years | |
| Omri Amirav-Drory | M | - |
Nanocarry Therapeutics Ltd.
Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | 3 years |
| Or Eisenberg | M | 43 | 3 years | |
| Hagit Binder | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Taub | M | 78 | 10 years | |
| Alon Yaar | M | 59 | - | |
| Larry Ellberger | M | 76 | 3 years | |
| Alla Felder | F | 51 | - | |
| Jonathan Kalman | M | 66 | - | |
| Michal Roytman | M | 39 | 1 years | |
| Wolfgang Ruttenstorfer | M | 73 | 1 years | |
| Ofra Levy-Hacham | M | 59 |
HealOr Ltd.
 HealOr Ltd. Pharmaceuticals: MajorHealth Technology HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel. | 5 years |
| Sharon Cohen-Vered | M | 57 | 10 years | |
| Andrew Udell | M | 54 | 1 years | |
| Roy Golan | M | 50 | 4 years | |
| Tami Yardeni | F | 52 | 2 years | |
| Tami Rachmilewitz | M | 54 | 2 years | |
| Elana Gazal | M | 49 | 5 years | |
| Yael Barak | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 34 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Revital Mandil–Levin
- Personal Network
